-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor Recently, Omega Therapeutics announced the completion of its investigational therapy OTX-2002 in clinical phase 1 trials Dosing of the
first patient.
OTX-2002 is designed for Treatment of patients with
relapsed or refractory hepatocellular carcinoma (HCC) and other solid tumors that overexpress MYC oncogenes.
The press release states that OTX-2002 is the first epigenomic controller based on novel programmable mRNA technology for patients
.
Liver cancer is the sixth most commonly diagnosed cancer in the world and the third most cancer-related death, with 75% of adult liver cancer patients having hepatocellular carcinoma
.
Tyrosine kinase inhibitors (TKIs) have been used as systemic treatments for hepatocellular carcinoma, but patients often develop resistance due to overexpression of MYC oncogenes
.
It is estimated that in up to 70% of patients with hepatocellular carcinoma, overexpression of MYC is associated
with the aggressiveness of hepatocellular carcinoma.
OTX-2002 is an epigenomic modulator
under development for the treatment of hepatocellular carcinoma.
This drug is an mRNA therapeutic delivered via lipid nanoparticles (LNP) that reduces MYC expression
by modulating the epigenome before transcription of the MYC gene.
In other words, OTX-2002 can control the expression of MYC gene without changing the sequence of this gene in cells, which has the potential to overcome the problem
of abnormal self-regulation of MYC in cancer.
Omega's previously published preclinical data support the mechanism of action and antitumor activity
of OTX-2002 in a variety of in vitro and in vivo models.
Multiple in vitro studies have demonstrated the ability of OTX-2002 to modulate the epigenomic profile of
MYC and control its pre-transcriptional expression.
OTX-2002, on the other hand, induces strong antitumor activity
in a variety of in vivo HCC models either alone or in combination with standard therapy.
In addition, the treatment of non-human primates with OTX-2002 successfully induced pre-transcriptional downregulation
of their hepatocyte MYC.
These accumulated preclinical data support the clinical potential
of OTX-2002 to provide new therapeutic strategies for liver cancer patients.
"Our first epigenomics modulator, OTX-2002, was administered for the first time in a patient, a milestone that represents an important step forward in our mission to bring a new engineered programmable mRNA therapy to patients," said Mahesh Karande, President and CEO of Omega Therapeutics.
Designed
for precise and long-lasting regulation of MYC expression.
We look forward to evaluating the effects of OTX-2002 for HCC and believe it has the potential to change the landscape
of care for patients in need.
" ”
first patient.
OTX-2002 is designed for Treatment of patients with
relapsed or refractory hepatocellular carcinoma (HCC) and other solid tumors that overexpress MYC oncogenes.
The press release states that OTX-2002 is the first epigenomic controller based on novel programmable mRNA technology for patients
.
Liver cancer is the sixth most commonly diagnosed cancer in the world and the third most cancer-related death, with 75% of adult liver cancer patients having hepatocellular carcinoma
.
Tyrosine kinase inhibitors (TKIs) have been used as systemic treatments for hepatocellular carcinoma, but patients often develop resistance due to overexpression of MYC oncogenes
.
It is estimated that in up to 70% of patients with hepatocellular carcinoma, overexpression of MYC is associated
with the aggressiveness of hepatocellular carcinoma.
OTX-2002 is an epigenomic modulator
under development for the treatment of hepatocellular carcinoma.
This drug is an mRNA therapeutic delivered via lipid nanoparticles (LNP) that reduces MYC expression
by modulating the epigenome before transcription of the MYC gene.
In other words, OTX-2002 can control the expression of MYC gene without changing the sequence of this gene in cells, which has the potential to overcome the problem
of abnormal self-regulation of MYC in cancer.
Omega's previously published preclinical data support the mechanism of action and antitumor activity
of OTX-2002 in a variety of in vitro and in vivo models.
Multiple in vitro studies have demonstrated the ability of OTX-2002 to modulate the epigenomic profile of
MYC and control its pre-transcriptional expression.
OTX-2002, on the other hand, induces strong antitumor activity
in a variety of in vivo HCC models either alone or in combination with standard therapy.
In addition, the treatment of non-human primates with OTX-2002 successfully induced pre-transcriptional downregulation
of their hepatocyte MYC.
These accumulated preclinical data support the clinical potential
of OTX-2002 to provide new therapeutic strategies for liver cancer patients.
Image source: 123RF
"Our first epigenomics modulator, OTX-2002, was administered for the first time in a patient, a milestone that represents an important step forward in our mission to bring a new engineered programmable mRNA therapy to patients," said Mahesh Karande, President and CEO of Omega Therapeutics.
Designed
for precise and long-lasting regulation of MYC expression.
We look forward to evaluating the effects of OTX-2002 for HCC and believe it has the potential to change the landscape
of care for patients in need.
" ”
Dr.
Yan Moore, Chief Medical Officer of Omega Therapeutics, added: "Given the critical role of MYC in disease progression, MYC has long been a popular target for cancer therapeutics, but the properties of MYC genes and proteins have made it an undruggable target
.
Omega's unique approach has the potential to pre-transcribal effects on MYC dysregulation at the source through epigenomics, thereby downregulating its expression
.
This mechanism of action may increase efficacy and improve safety
compared to currently available treatments.
”
WuXi AppTec provides integrated, end-to-end new drug R&D and manufacturing services to the global biopharmaceutical industry, covering chemical drug R&D and manufacturing, biological research, preclinical testing and clinical trial R&D, cell and gene therapy R&D, testing and manufacturing
.
If you have related business needs, please click the picture below to fill in the specific information
.
